ADRx, Inc., founded in Westlake Village, California, is a pre-clinical stage biopharmaceutical company focused on developing novel drugs to treat amyloid diseases. Leveraging breakthrough technology, ADRx transforms atomic structures into small molecule therapies targeting conditions such as Alzheimer’s, ALS, and Parkinson’s Disease. The company is pioneering the application of structure-based design to disrupt protein aggregation diseases, aiming to address significant unmet medical needs in neurodegenerative disorders.
Notable figures associated with ADRx include leading scientists and industry experts in biopharmaceuticals. The company has garnered attention for its innovative drug discovery platform and its ability to identify, design, and develop therapeutics based on patient-derived pathological proteins. ADRx’s advancements have the potential to significantly impact the treatment landscape for amyloid diseases, positioning it as a key player in the field of neurodegenerative disease research.
